
CLAIMS

1. A compound according to formula (I),



(I); wherein:

each R^A is independently $*L^1$-X^1, wherein * indicates the point of attachment to the remainder of the molecule, each L^1 is independently selected from bond, O, S, SO, SO_2, C≡C, C(=O), *C(=O)-O**, C_1-C_6alkylene, C_1-C_6haloalkylene, *O-C_1-C_6alkylene**, *O-C_1-C_6haloalkylene**, *O-C_1-C_6hydroxyalkylene**, C_1-C_6alkylene-O-C_1-C_6alkylene, *O-C_3-C_6cycloalkylene**, *O-3-6 membered heterocyclylene**, C_1-C_6hydroxyalkylene, C_3-C_6cycloalkylene, 3-6 membered heterocyclylene (e.g. comprising 1 heteroatom which is O), O-C_1-C_6alkylene-O, *O-C_1-C_6alkylene-O-C_3-C_6cycloalkylene** and *O-C_1-C_6alkylene-O-3-6 membered heterocyclylene**, wherein * indicates the point of attachment to the remainder of the molecule, and ** indicates the point of attachment to X^1;

and each X^1 is independently selected from H, halo, cyano, hydroxyl, C_1-C_6alkyl, C(=O)-C_1-C_6alkyl, C_1-C_6haloalkyl, C_3-C_6cycloalkyl substituted by 0-3 R^8 groups, O-C_1-C_6alkyl, S-C_1-C_6alkyl, S(O)-C_1-C_6alkyl, $S(O)_2$-C_1-C_6alkyl, $N(C_1$-C_6alkyl$)_2$, $C(=O)N(C_1$-C_6alkyl$)_2$, C_1-C_6hydroxyalkyl, 3-6 membered heterocyclyl (e.g. comprising 1 or 2 heteroatoms independently selected from O, N and S) substituted by 0-3 R^8 groups, 5-10 membered heteroaryl (e.g. 5, 6, 9 or 10 membered heteroaryl) comprising 1-4 heteroatoms independently selected from O, N and S substituted by 0-3 R^8 groups, 5-10 membered partially saturated heterocyclyl comprising 1 to 4 heteroatoms independently selected from the group consisting of O, N and S substituted by 0-3 R^8 groups, 7-10 membered spiroheterocyclyl comprising 1 or 2 heteroatoms independently selected from O, N and S substituted by 0-3 R^8 groups and C_7-C_{10}spirocycloalkyl substituted by 0-3 R^8 groups; and

each R^8 is independently selected from the group consisting of C_1-C_6alkyl, C(=O)C_1-C_6alkyl, halo, C_1-C_6haloalkyl, S-C_1-C_6alkyl, SO-C_1-C_6alkyl, SO_2-C_1-C_6alkyl, cyano, hydroxyl, or wherein two R^8 substituents on the same ring atom join together to form =O;

or a pharmaceutically acceptable salt and/or tautomer thereof.

2. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to claim 1, wherein R^A is selected from:

a) halo,
b) cyano,
c) C_1-C_6alkyl,
d) C_1-C_6haloalkyl,
e) C_1-C_6hydroxyalkyl,
f) O-C_1-C_6alkyl,
g) C(=O)-O-C_1-C_6alkyl,
h) C_1-C_6alkylene-O-C_1-C_6alkyl,
i) O-C_1-C_6alkylene-O-C_1-C_6alkyl,
j) C_3-C_6cycloalkyl substituted by 0-3 R^8 groups,
k) 5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R^8 groups,
l) 5-10 membered partially saturated heterocyclyl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R^8 groups,
m) O-C_3-C_6cycloalkyl substituted by 0-3 R^8 groups,
n) C≡C-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R^8 groups,
o) S-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R^8 groups,
p) C_1-C_6alkylene-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R^8 groups,
q) O-C_1-C_6haloalkyl,
r) O-C_1-C_6alkylene-N(C_1-C_6alkyl)$_2$,
s) O-C_1-C_6hydroxyalkylene-O-C_1-C_6alkyl,
t) O-C_1-C_6alkylene-C_3-C_6cycloalkyl substituted by 0-3 R^8 groups,
u) O-C_1-C_6alkylene-3-6 membered heterocyclyl comprising 1 or 2 heteroatoms independently selected from O, N and S substituted by 0-3 R^8 groups,
v) O-C_1-C_6alkylene-C(=O)-N(C_1-C_6alkyl)$_2$,
w) C_1-C_6alkylene-5-10 membered partially saturated heterocyclyl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R^8 groups,
x) O-C_1-C_6alkylene-7-10 membered spiroheterocyclyl comprising 1 or 2 heteroatoms independently selected from O, N and S substituted by 0-3 R^8 groups,

y) O-C_1-C_6alkylene-S(O)$_2$-C_1-C_6alkyl,

z) O-C_1-C_6hydroxyalkyl,

aa) O-C_1-C_6alkylene-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R^8 groups,

bb) O-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R^8 groups,

cc) O-3-6 membered heterocyclyl comprising 1 or 2 heteroatoms independently selected from O, N and S substituted by 0-3 R^8 groups,

dd) C≡C-C_3-C_6cycloalkyl substituted by 0-3 R^8 groups,

ee) S-C_1-C_6haloalkyl,

ff) O-C_1-C_6alkylene-O-3-6 membered heterocyclyl comprising 1 or 2 heteroatoms independently selected from O, N and S substituted by 0-3 R^8 groups, and

gg) 3 to 6 membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S substituted by 0-3 R^8 groups.

3. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to claim 2, wherein each R^8 is independently selected from the group consisting of halo (e.g. fluoro), C_1-C_6alkyl (e.g. methyl), hydroxyl, cyano, S(O_2)-C_1-C_6alkyl (e.g. S(O_2)CH_3), C(=O)-C_1-C_6alkyl (e.g. C(=O)CH_3), O-C_1-C_6alkyl (e.g. OCH_3) and C_1-C_6haloalkyl (e.g. C_1haloalkyl, e.g. CHF_2), or wherein two R^8 substituents on the same ring atom join together to form =O.

4. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to claim 2, wherein:

R^A is selected from halo, cyano, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, O-C_1-C_6alkyl, C(=O)-O-C_1-C_6alkyl, C_1-C_6alkylene-O-C_1-C_6alkyl, O-C_1-C_6alkylene-O-C_1-C_6alkyl, C_3-C_6cycloalkyl and 3 to 6 membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S.

5. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of the preceding claims, wherein R^A is CH_3, OCH_3 or OCH_2CH_3.

6. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to claim 1, wherein each L^1 is independently selected from bond, O, C(=O), *C(=O)-O**, C_1-C_6alkylene, C_1-C_6haloalkylene, *O-C_1-C_6alkylene**, C_1-C_6alkylene-O-C_1-C_6alkylene, C_1-C_6hydroxyalkylene, C_3-C_6cycloalkylene, 3-6 membered heterocyclylene (e.g. comprising 1 heteroatom which is O) and O-C_1-C_6alkylene-O, wherein *indicates the point of attachment to the remainder of the molecule, and ** indicates the point of attachment to X^1;

and each X^1 is independently selected from H, halo, cyano, hydroxyl, C_1-C_6alkyl, C_1-C_6haloalkyl, C_3-C_6cycloalkyl, O-C_1-C_6alkyl, C_1-C_6hydroxyalkyl and 3-6 membered heterocyclyl (e.g. comprising 1 heteroatom that is O).

7. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to claim 1 or claim 2, wherein R^A is selected from the list consisting of C_1-C_6alkyl, C_1-C_6alkylene-O-C_1-C_6alkyl, C_1-C_6haloalkyl, C(=O)-O-C_1-C_6alkyl, C_1-C_6hydroxyalkyl, 3-6 membered heteroatom comprising 1 heteroatom that is O, halo, O-C_1-C_6alkyl, C_3-C_6cycloalkyl, cyano and O-C_1-C_6alkylene-O-C_1-C_6alkyl.

8. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to claim 1, selected from any one of:

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-methyl-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-(difluoromethyl)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

methyl 4-((7'-((1R,3R)-3-hydroxycyclohexyl)-6'-oxo-6',7'-dihydrospiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-2'-yl)amino)-1H-pyrazole-3-carboxylate;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(hydroxymethyl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(tetrahydrofuran-3-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-methoxy-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-chloro-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-cyclopropyl-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(trifluoromethyl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

4-((7'-((1R,3R)-3-hydroxycyclohexyl)-6'-oxo-6',7'-dihydrospiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-2'-yl)amino)-1H-pyrazole-3-carbonitrile;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(2-methoxyethoxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-ethoxy-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-(((3R,4R)-4-fluorotetrahydrofuran-3-yl)oxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-(((3S,4S)-4-fluorotetrahydrofuran-3-yl)oxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-(((3R,4S)-4-fluorotetrahydrofuran-3-yl)oxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-(((3S,4R)-4-fluorotetrahydrofuran-3-yl)oxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-(3,3-difluorocyclobutoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-(3,3-difluorocyclobutoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((5'-(difluoromethyl)-1'-methyl-1H,1'H-[3,4'-bipyrazol]-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-((S)-2,2-difluorocyclopropyl)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-((S)-2,2-difluorocyclopropyl)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((1'-(difluoromethyl)-1H,1'H-[3,4'-bipyrazol]-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-((1-methyl-1H-pyrazol-4-yl)oxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyridin-3-ylethynyl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((1',5'-dimethyl-1H,1'H-[3,4'-bipyrazol]-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-(cyclopropylmethoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-(2-fluoroethoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-cyclobutoxy-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-(2,2-difluoroethoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(2-hydroxyethoxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-((1-methyl-1H-pyrazol-3-yl)methoxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-(2,2-difluoro-3-methoxypropoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-((1-fluorocyclopropyl)methoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-((1-(2,2,2-trifluoroethyl)azetidin-3-yl)oxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-(5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-((3-fluorooxetan-3-yl)methoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(methoxy-d3)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-(((3R,4R)-4-fluoro-1-methylpyrrolidin-3-yl)oxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-(((3S,4S)-4-fluoro-1-methylpyrrolidin-3-yl)oxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(methylthio)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-((2-acetyl-2-azaspiro[3.3]heptan-6-yl)methoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-((2-oxaspiro[3.3]heptan-6-yl)methoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-cyclopropoxy-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(2,2,2-trifluoroethoxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((5'-chloro-1'-methyl-1H,1'H-[3,4'-bipyrazol]-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(prop-1-yn-1-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyridin-4-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyridin-2-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyridin-3-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((1'-(difluoromethyl)-5'-methyl-1H,1'H-[3,4'-bipyrazol]-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(((R)-tetrahydrofuran-3-yl)oxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyrazolo[1,5-a]pyrazin-3-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-(((1r,3R)-3-hydroxy-3-methylcyclobutyl)methoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-(((R)-1,4-dioxan-2-yl)methoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

1-(((4-((7'-((1R,3R)-3-hydroxycyclohexyl)-6'-oxo-6',7'-dihydrospiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-2'-yl)amino)-1H-pyrazol-3-yl)oxy)methyl)cyclopropane-1-carbonitrile;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-((methylthio)methyl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-((S)-2,2-difluorocyclopropoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-((R)-2,2-difluorocyclopropoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(((R)-tetrahydrofuran-3-yl)methoxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(((S)-tetrahydrofuran-3-yl)methoxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-((tetrahydro-2H-pyran-4-yl)oxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-((-4-fluorotetrahydrofuran-3-yl)methoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-((4,4-difluorotetrahydrofuran-3-yl)methoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-hydroxy-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one.;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(((S)-tetrahydrofuran-3-yl)oxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((1'-methyl-1H,1'H-[3,3'-bipyrazol]-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((1'-methyl-1H,1'H-[3,4'-bipyrazol]-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-((1r,3R)-3-methoxycyclobutoxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;


2'-((3-(1,3,4-oxadiazol-2-yl)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((1'-methyl-5'-(trifluoromethyl)-1H,1'H-[3,4'-bipyrazol]-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;

2'-((3-(1-(fluoromethyl)cyclopropoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;


or a pharmaceutically acceptable salt and/or tautomer thereof.

9. The compound according to claim 1 or claim 8, wherein the compound is




, or a pharmaceutically acceptable salt and/or tautomer thereof.

10. The compound according to claim 1 or claim 8, wherein the compound is




, or a pharmaceutically acceptable salt and/or tautomer thereof.

11. The compound according to claim 1 or claim 8, wherein the compound is




, or a pharmaceutically acceptable salt and/or tautomer thereof.

12. The compound according to claim 1 or claim 8, wherein the compound is



, or a pharmaceutically acceptable salt and/or tautomer thereof.

13. The compound according to claim 1 or claim 8, wherein the compound is



, or a pharmaceutically acceptable salt and/or tautomer thereof.

14. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of the preceding claims and one or more pharmaceutically acceptable carriers.

15. A combination comprising the compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of claims 1 to 13, and one or more therapeutically active agents.

16. A compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of claims 1 to 13 for use as a medicament.

17. Use of the compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of claims 1 to 13 in the manufacture of a medicament for the treatment of cancer.

18. The use according to claim 17, wherein the cancer is selected from ovarian cancer, gastric cancer, uterine cancer, breast cancer (e.g. ER+ breast cancer, e.g. ER+/Her2- breast cancer), lung cancer and endometrial cancer.

19. The use according to claim 17 or claim 18, wherein the cancer is a cyclin E amplified cancer.

20. The use according to any one of claims 17-19, wherein the use comprises modulating CDK2 activity in a subject.